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Objectives. To test the physical properties and host response to the bioceramic particles, silica-calcium phosphate (SCPC10) and
Cristobalite, in a rat animal model and compare their biocompatibility to the current clinically utilized urethral bulking materials.
Material and Methods. The novel bulking materials, SCPC10 and Cristobalite, were suspended in hyaluronic acid sodium salt
and injected into the mid urethra of a rat. Additional animals were injected with bulking materials currently in clinical use.
Physiological response was assessed using voiding trials, and host tissue response was evaluated using hard tissue histology
and immunohistochemical analysis. Distant organs were evaluated for the presence of particles or their components. Results.
Histological analysis of the urethral tissue five months after injection showed that both SCPC10 and Cristobalite induced a more
robust fibroblastic and histiocytic reaction, promoting integration and encapsulation of the particle aggregates, leading to a larger
bulking effect. Concentrations of Ca,Na, Si, and P ions in the experimental groupswere comparable to control animals.Conclusions.
This side-by-side examination of urethral bulking agents using a rat animal model and hard tissue histology techniques compared
two newly developed bioactive ceramic particles to three of the currently used bulking agents. The local host tissue response and
bulking effects of bioceramic particles were superior while also possessing a comparable safety profile.
1. Introduction
Approximately 130,000 surgical procedures are performed
annually to treat stress urinary incontinence (SUI) in the US
[1]. Urethral bulking therapy (UBT) was used frequently in
the 1990s but lost popularity due to three main reasons: first,
disappointing long-term efficacy; second, complications
related to local host tissue response and distant tissue
migration; and third, a dramatic increase in the use of
polypropylene mesh. SUI treatment using mesh has, in some
cases, led to severe and sometimes irreversible complications
resulting in an FDA warning first released in 2008 and then
again in 2011 [2, 3]. Subsequent to the warnings, there was
a resurgence of interest in other forms of treatment for SUI
[4]. Provided its limitations are resolved, UBT represents
an ideal treatment for poor surgical candidates, patients
with comorbidities, placing them in a high-risk category for
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Complications related to the use of synthetic material in
the treatment of SUI highlight a need for preclinical studies.
Experimental animal models could be used to help assess
and solve the fundamental problem associated with UBT, the
absence of an ideal bulking material. The urethral bulking
agent should be stable, easy to inject, nonimmunogenic,
permanent, nonmigratory, nonerosive, and easily stored and
handled and should possess a high safety profile [6]. All these
properties can be tested on laboratory animals; however only
a few such preclinical studies have been performed to date [7,
8].We recently described a rat model for preclinical testing of
urethral bulking agents, including hardmicroparticle bulking
therapy [9]. In this study, we present a preclinical experiment
comparing two new bioactive ceramic bulking materials to
the three bulking agents most commonly used in treatment
of SUI.
The two new bulking materials we tested were silica-
calcium phosphate (SCPC10) and Cristobalite. Both of these
bioactive ceramic particles have been studied extensively in
bone regeneration [10]. Previous studies documented that
bioceramics stimulate tissue attachment to the porous surface
through serum protein adsorption, tissue formation, and
cell attachment [11]. The chemical stability of bioceramics
depends on the chemical composition and crystalline phases,
which can be controlled by thermal treatment and compact
pressure during the manufacturing process [12]. In addition,
we used a new formulation of hyaluronic acid sodium
salt, sodium hyaluronate, Hyaluronan (HA), with optimized
viscosity, which gets absorbed by the body, leaving only
the particles at the injection site where they can interact
directly with the tissue. We suspended the two different
experimental, bioceramic particles in HA and injected them
into the proximal urethra of a rat. As a control, we used
bulking materials that are currently in clinical use: silicon
particles (Macroplastique, Uroplasty Inc, Minneapolis, MN,
USA), calcium-hydroxyapatite particles (Copatite, Boston
Scientific, Natic, MA, USA), and polyacrylamide hydrogel
(Bulkamid, Contura International, Soeborg, Denmark). We
used hard tissue histology techniques to evaluate particle
integrity, incorporation, and host tissue reaction. In addition,
we harvested the distal organs and tested them for the
presence of particle and/or trace levels of their components.
2. Material and Methods
An individual bulking agent was injected into the proximal
urethra of 21 femaleWistar rats. Six animals per experimental
group were injected with either SCPC10 or Cristobalite and
three animals per control group were injected with Coaptite,
Bulkamid, or Macroplastique. Organs from three healthy
animals were harvested as normal controls.
2.1. Preparation of Bioceramic Particles, HA Suspension. HA,
prepared in double-distilled water (ddH
2
O), was used as the
suspension media for the two experimental bulking agents.
According to our previous research, we used HA (molecular
weight of 900 kDa) at a 2.5% concentration with a bioceramic
particle to HA ratio of 1 : 4 [9]. The suspension mixture was
sterilized in an autoclave for 20 minutes at 121∘C. Viscosity
of the 2.5% HA solution was approximately 80,000 cP prior
to sterilization and decreased to approximately 30,000 cP fol-
lowing sterilization due to a slightly lower molecular weight,
which is caused by heat-induced depolymerization of the HA
molecule. pH of the material was 7.2 and remained within the
physiological range after dissolving in water. Once sterilized,
the solutionwasmixed on amixing plate for 12 hours, or until
the bioceramic particles were evenly distributed throughout
the suspension media.
2.2. Injection. Female Wistar rats, 6-7 months old (Charles
River Laboratories, Saint-Constant, Quebec, Canada), were
maintained under standard laboratory conditions with free
access to food and water. The University of Vermont Institu-
tional Animal Care and Use Committee approved all animal
procedures, and appropriate measures were taken to mini-
mize pain and discomfort to the animals. Under inhalation
anesthesia, through a lower midline abdominal incision, the
mid urethra was bluntly dissected to expose the injection site.
Using direct visualization with an operating microscope, the
urethral bulking agent was injected into the wall of the mid
urethra.This injection technique was previously described in
depth [9]. Microphotographs were taken to record any gross
abnormalities.
2.3. Tissue Harvesting. Five months after injection, under
general inhalation anesthesia, a midline abdominal incision
was made and the urethra was exposed. Following removal
of the urethra, the lungs, kidneys, liver, and spleen were
harvested to test for levels of particle ions. All tissues were
immediately fixed in an ethanol-based fixative, HistoChoice
(Amresco, Solon, OH), for 7 days at room temperature.
2.4. Histological Analysis. Urethral specimens were pro-
cessed using a novel technique, which facilitates immunohis-
tochemical analysis on tissues containing hard particles [13–
15]. It involves embedding the specimen in resin and cutting
the sections using a sawing microtome (Leitz 1600, Wetzlar,
Germany). This method was previously described in detail
[9]. Immunohistochemical staining was performed using
a primary mouse monoclonal antibody specific to tumor
necrosis factor-alpha (TNF-𝛼, Abcam Ltd., Cambridge, UK).
Additional sections were stained using Giemsa surface stain
[16]. A pathologist evaluated the urethral cross-sections to
determine bead morphology and host tissue reaction.
2.5. Scanning Electron Microscopy (SEM). Bioceramic parti-
cles were analyzed with SEM prior to suspension and injec-
tion. The size, shape, and integrity of the bulking material
were evaluated.
2.6. Evaluation of Distant Organs for the Presence of Particles
andTheir Components. Following tissue digestion, filtration,
and centrifugation, the liver, kidneys, spleen, and lungs were
examinedmicroscopically for the presence of whole particles.
Subsequently, organs were digested in 70% HNO
3
and the
concentration of Si, P, Ca, and Na was measured using
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Figure 2: Cross-sections of urethra 5 months after injection of SCPC10 particles. (a) Cross-sectional view of entire urethra with nodular
particle packets in the submucosa and adventitia (10x magnification). Arrows indicate particle masses. (b) Particle packet in a well
circumscribed nodule showing some surface irregularities and size variability of the individual particles (20x magnification).
inductively coupled plasma optical emission spectroscopy. A
control experiment was run in parallel using organs from
normal, noninjected animals.
2.7. Statistical Analysis. Quantitative values were presented
as means ± standard error of the mean. All statistical
calculations were performed using GraphPad PRISM (San
Diego, CA, USA). Paired data were evaluated using a two-
tailed Student’s t-test. A one-way analysis of variance was
used for comparisons ofmultiple groups. P values≤ 0.05 were
considered statistically significant.
3. Results
3.1. SEM Evaluation of Bioceramic Particles. Cristobalite par-
ticles were cuboidal in shape, with a cross-section size of 75–
200 micrometers. Significant variation in the shape and size
was noted among the SCPC10 particles, which displayed a
coral-like appearance with multiple pores (Figure 1).
3.2. Intraoperative Examination. In vivo examination under
the operating microscope of Cristobalite and SCPC10
particles 5 month after injection did not reveal any gross
abnormalities. No signs of abscess formation, acute inflam-
matory changes, or florid scarring of the host tissue were
noted.These observations were comparable to those obtained
immediately following injection.
3.3. Histological Examination
3.3.1. SCPC10. Cross-sections of the injection site showed
coaptation of the urethral mucosa, with the particles located
in the submucosa and urethral smooth muscle. Surface
irregularities of individual particles were noted on high-
power light microscopy. Collagen fibers were densely packed
around the particle mass. Immunostaining did not reveal
active macrophages, signs of a robust foreign body response,
or scarring. Fibroblastic proliferation around individual par-
ticles resulted in a 1.5–2 times larger volume than the injected
particle mass alone (Figure 2).
3.3.2. Cristobalite. Particle aggregates were seen scattered
throughout the urethral cross-sections. The aggregates were
polyhedral in shape and were integrated into the tissue





Figure 3: Cross-sections of rat urethra 5 months after injection of Cristobalite particles. (a) Cross-sectional view of the entire urethra (10x






Figure 4: (a) Cross-sections of urethra 5 months after injection of Coaptite (10x magnification). Arrow pointing to particle mass. (b) Image
showing particles surrounded by fibroblasts and giant cells. Relatively uniform size of the injected particles.
due to the surrounding mild host reaction. Fibroblastic
proliferation around the particle masses and between the
individual particles was noted.This proliferation resulted in a
volume 2-3 times larger than the injected particle mass alone,
which was noted on the urethral lumen. Some histiocytes
were interspersed among the fibroblasts, indicating a mild
histiocytic reaction. The particles were seen as a mass in the
adventitia as well as the submucosa of the urethra (Figure 3).
Overall, for both SCPC10 andCristobalite, aminor host tissue
response without florid scarring was visualized using light
microscopy. The presence of macrophages and a host tissue
inflammatory response was ruled out with negative TNF
alpha staining.
3.3.3. Coaptite. Compared to the bioceramic particles, there
were less fibroblastic changes with less mass effect. The
increase in volume was approximately twofold. Fibrob-
lastic proliferation was more localized and nodular and
was surrounded by giant cells. The injected material was
primarily seen in aggregates, with each aggregate containing
a variable amount of material. There were also aggregates of
histiocytes with giant cells interspersed. The contour of each
individual calcium hydroxylapatite particle was relatively
uniform. Coaptite showed calcium-hydroxyapatite particles
uniform in size (70–125 microns) surrounded by fibroblasts
and collagen (Figure 4).
3.3.4. Bulkamid. There were two distinct types of host tissue
reaction: diffuse fibroblastic changes and nodular aggregates
with mild fibroblastic proliferation.The diffuse changes were
surrounded by fibroblasts, resulting in an increased volume of
approximately 3-fold.The nodular type of reaction resulted in
a volume increase of approximately 2-fold. The volume effect
and fibroblastic reaction seen in the nodular tissue changes
were similar to those seen with Coaptite. There was a large
variation in size of the nodular aggregates spread throughout
the tissue. Distribution of the bulking agent was seen in the





Figure 5: Cross-sections of urethra 5 months after injection of Bulkamid. (a) Cross-section of urethra without large injection mass (10x
magnification). (b) Image showing small injection aggregates in a nodular type of reaction with mild surrounding fibroblastic changes (20x





Figure 6: Cross-sections of urethra 5 months after injection of Macroplastique. (a) Cross-section of entire urethra (10x magnification).
Arrows indicate bulkingmaterial mass in the adventitia and suburothelium. (b) Injected bulkingmaterial with some surrounding fibroblastic
proliferation (20x magnification).
adventitia and submucosa.The only tissue change noted with
Bulkamid was mild fibroblastic proliferation (Figure 5).
3.3.5. Macroplastique. This bulking agent also displayed two
distinct reaction types to the injected material: nodular
aggregates and a more diffuse fibroblastic type of reaction.
The nodular aggregates of material appeared to be some-
what band-like, partially folded onto itself, and surrounded
predominantly by histiocytes. This resulted in an increase in
volume of approximately 1.5-fold.Themore diffuse reaction is
primarily a fibroblastic reaction with mild, thin proliferation
surrounding the injected bead masses. The injected material
aggregates varied significantly in size and shape. Individual
silicone beads varied in size by a factor of 8. Particles were
organized in collagen-encapsulated clusters with evidence of
mild fibroblast in-growth (Figure 6).
3.4. Evaluation of Distant Organs. There were no particles
detected in the distant organs. Animals injected with Cristo-
balite and Macroplastique appeared to have higher Si con-
centrations in the lungs; nevertheless, the ion concentrations
in all of the organs were within the biological range. Trace
components (Si, P, Ca, and Na elements) from SCPC10
and Cristobalite showed comparable concentrations to the
other injected bulking agents and the healthy, intact controls
(Figure 7).
4. Discussion
The use of urethral bulking therapy declined significantly
over the course of the last two decades, in part, due to an
increase in the use of anti-incontinence procedures using
polypropylene mesh. It has been well documented that this



















































































































Figure 7: Bar graphs summarizing the ion levels of particle components in the distant organs.
therapy is not suitable for every patient and can be associated
with serious complications [17, 18]. Complications from
UBT are linked to the degradation of synthetic material,
causing local inflammatory changes, or distant migration
of the material or its components [19, 20]. UBT-induced
complications were most pronounced with the use of poly-
tetrafluoroethylene (Telfon), popularized in the 1970s [21].
Teflon is not a biologically inert substance, which leads to
significant scarring as well as a foreign body granulomatous
reaction locally and distantly from migration of the particles
[22, 23].
We compared two types of bioactive ceramic particles,
suspended in sodium hyaluronate, to bulking materials
currently being used clinically, and assessed the propensity
of these materials to cause complications due to local host
tissue reaction and distant migration. Sodium hyaluronate
is the sodium salt of hyaluronic acid. It is a natural, linear,
unbranched polysaccharide belonging to the class of nonsul-
phated glycosaminoglycans. It occurs naturally in the human
body, especially in the vitreous humor and synovial fluid,
and as a major component in the extracellular matrix in
the skin. It proved to be the optimal suspension media. Its
high viscosity prevents plugging of the needle and facilitates
uniform particle suspension. The propensity for absorption
allows the surface of the bioceramic particles to better interact
with the host tissue, preventing migration and providing an
optimal bulking mass. The rate at which Hyaluronan gets
absorbed by the body is tissue specific and depends on the
flow of body fluids in the specific tissue as well as the viscosity.
An additional advantage is that it does not significantly
change its properties during the sterilization process [24].
Injections of SCPC10 particles showed fibroblastic prolif-
eration, which is needed to hold the particle mass in place.
Significant variation in particle size raises the concern that
they may migrate to distant organs, which was previously
documented on particles smaller than 80 microns [25].
However, no evidence of migration of particles or their
components was documented in this study. When com-
pared to the commonly used bulking agents, both SCPC10
and Cristobalite produced a more robust fibroblastic and
histiocytic reaction, which in turn helped to integrate and
encapsulate the particle aggregates. In vivo, this property
effectively anchors the particles in the target tissue and
generates a larger bulking effect. Cristobalite, which has
the same inherent properties as SCPC10 but shows more
regularity in shape and size, induced stronger fibroblastic
proliferation, which in turn resulted in a larger bulking effect.
Microscopic examination of tissue injected with Cristobalite
was most similar to the response seen with Macroplastique
but displayed some important differences. Macroplastique
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particle aggregates were encapsulated by a thin fibroblastic
and histiocytic reaction causing less of a mass effect. When
comparing all particle types, it appears that round particles
elicit less of a fibroblastic tissue reaction.
Comparable levels of Ca, Na, and P ions were noted
in the distant organs of all experimental animals. Animals
injected with SCPC10 had comparable Si levels to healthy,
noninjected controls and animals injected with Cristobalite
and Macroplastique appeared to have higher concentrations
of Si than controls. Nevertheless, the concentration in all
organs was within the biological range [26]. The particle
migration seen with previously introduced bulking agents
represents a major complication, which has serious and
even fatal consequences [27]. For some substances (Teflon,
Durasphere, and autologous fat),migrationwas detected only
after broader clinical use. Testing for the presence of particle
ions is a novel method that provides additional evidence on
the safety of these new materials. The absence of particles
and their components in distant organs, shown in our study,
provides initial safety data. However, experiments conducted
using a rodent model do not provide a final guarantee of
clinical safety. We plan to repeat these preclinical trials using
larger animals.
In this study, we performed a comprehensive, side-
by-side comparison of urethral bulking agents utilizing a
previously established rat animal model in combination with
hard tissue histologic and immunohistochemical analysis. On
this basis, two newly developed bioactive ceramic particles,
suspended in sodium hyaluronate, were compared to three
currently used urethral bulking agents. The local host tissue
response and bulking effects of both SCPC10 and Cristobalite
were superior while also possessing a comparable safety
profile. Although further studies are necessary, this research
suggests that Cristobalite, suspended in sodium hyaluronate,
produces a superior bulking effect and can provide the
improved, durable long-term response needed for successful
urethral bulking therapy.
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